Updates are available Correction dated 2023-01-03
Click to view Correction: https://doi.org/10.1038/s41588-022-01288-5
-
Authors
-
Funding
Funding for this research was provided by:
Ludwig Institute for Cancer Research
LUNGevity Foundation
- License Information
-
More Information
Article History
Received: 1 August 2022
Accepted: 17 October 2022
First Online: 28 November 2022
Change Date: 3 January 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41588-022-01288-5
Competing interests
: L.F.S. declares no competing interests. R.R.W. reports having stock and other ownership interests with Boost Therapeutics, ImmVira LLC, Reflexion Pharmaceuticals, Coordination Pharmaceuticals Inc., Magi Therapeutics and Oncosenescence; serving in a consulting or advisory role for Aettis Inc., AstraZeneca, Coordination Pharmaceuticals, Genus, Merck Serono S.A., NanoProteagen, NKMax America Inc., Shuttle Pharmaceuticals and Highlight Therapeutics, S.L.; having research grants with Varian and Regeneron; and receiving compensation including travel, accommodations or expense reimbursement from AstraZeneca, Boehringer Ingelheim Ltd. and Merck Serono S.A. S.P.P. has patents outside of the submitted work.
